Trav17 inhibitors are a class of chemical compounds designed to specifically target and modulate the activity of the Trav17 protein or receptor. These inhibitors typically achieve their function by binding to the active site of the Trav17 protein, preventing the natural substrate or ligand from interacting with it. This blockage disrupts the normal biochemical pathway in which the Trav17 protein plays a role. In some cases, Trav17 inhibitors may bind to allosteric sites, which are regions on the protein separate from the active site. Allosteric inhibition can induce conformational changes in the protein, altering its structure and diminishing its function. The binding interactions between Trav17 inhibitors and the protein typically involve a variety of non-covalent forces, including hydrogen bonds, van der Waals interactions, electrostatic forces, and hydrophobic contacts. These interactions contribute to the stability and specificity of the inhibitor within the binding pocket of the Trav17 protein.
Structurally, Trav17 inhibitors are highly diverse, ranging from small organic molecules to larger, more complex structures. Common features of these inhibitors include aromatic rings, heterocycles, and functional groups such as hydroxyl, amine, and carboxyl groups. These chemical features enhance the inhibitor's ability to interact with specific residues in the Trav17 protein's binding sites. The physicochemical properties of Trav17 inhibitors, including molecular weight, polarity, solubility, and lipophilicity, are carefully designed to ensure optimal binding affinity and specificity. For instance, hydrophobic regions within the inhibitor structure may interact with non-polar regions of the Trav17 protein, while polar or charged groups can engage in hydrogen bonding or ionic interactions with polar residues. These properties are balanced to ensure the inhibitors remain stable and soluble in biological environments, allowing them to effectively target the Trav17 protein and modulate its function.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Staurosporine | 62996-74-1 | sc-3510 sc-3510A sc-3510B | 100 µg 1 mg 5 mg | $82.00 $150.00 $388.00 | 113 | |
Staurosporine inhibits protein kinases, which could lead to the inhibition of phosphorylation processes necessary for Trav17 activity. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin inhibits phosphoinositide 3-kinases, potentially reducing PI3K/Akt signaling that may be essential for Trav17 function. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor which could reduce the activation of downstream kinases relevant to Trav17 activity. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin binds to FKBP12 and inhibits mTOR, which could suppress signaling pathways necessary for Trav17 function. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor, potentially inhibiting the MAPK/ERK pathway, which may be crucial for Trav17 activity. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, potentially inhibiting cellular responses that may be necessary for Trav17 function. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is a JNK inhibitor, potentially blocking the JNK signaling pathway which may be essential for Trav17 activity. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 inhibits MEK1/2, potentially preventing the activation of the MAPK/ERK pathway relevant to Trav17 function. | ||||||
Dasatinib | 302962-49-8 | sc-358114 sc-358114A | 25 mg 1 g | $47.00 $145.00 | 51 | |
Dasatinib is a Src-family kinase inhibitor, which could inhibit critical phosphorylation steps necessary for Trav17 signaling. | ||||||
PP 2 | 172889-27-9 | sc-202769 sc-202769A | 1 mg 5 mg | $92.00 $223.00 | 30 | |
PP2 is a Src kinase inhibitor, which could impede phosphorylation processes that are essential for Trav17 signaling pathways. | ||||||